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Enteropeptidase (enterokinase [E.C.3.4.21.9]) is a serine protease of the intestinal brush border in the proximal
small intestine. It activates the pancreatic proenzyme trypsinogen, which, in turn, releases active digestive enzymes
from their inactive pancreatic precursors. Congenital enteropeptidase deficiency is a rare recessively inheriteddisorder
leading, in affected infants, to severe failure to thrive. The genomic structure of the proenteropeptidase gene (25
exons, total gene size 88 kb) was characterized in order to perform DNA sequencing in three clinically and
biochemically proved patients with congenital enteropeptidase deficiency who were from two families. We found
compound heterozygosity for nonsense mutations (S712X/R857X) in two affected siblings and found compound
heterozygosity for a nonsense mutation (Q261X) and a frameshift mutation (FsQ902) in the third patient. In
accordance with the biochemical findings, all four defective alleles identified are predicted null alleles leading to a
gene product not containing the active site of the enzyme. These data provide first evidence that proenteropeptidase-
gene mutations are the primary cause of congenital enteropeptidase deficiency.
Introduction
Enteropeptidase (synonym: enterokinase [E.C.3.4.21.9])
was discovered, by N. P. Schepovalnikow in 1899 (Wal-
ther 1900), as a factor that is contained in the duodenum
and that is capable of activating pancreatic juice to digest
fibrin. Enteropeptidase acts as a sequence-specificprotease
(Maroux et al. 1971) activating trypsinogen by cleaving
off an inhibitory portion. Trypsin, in turn, releases chy-
motrypsin, carboxypeptidases, elastases, and also lipases
from their inactive pancreatic precursors. Intestinal acti-
vation of pancreatic precursors is the physiologic mech-
anism preventing the damage that proteases would cause
if theywere activewithin the pancreatic-duct system.Con-
sequently, protein digestion is expected to be largely de-
pendent on enteropeptidase activity. Enteropeptidase is
exclusively expressed in the brush border of the proximal
small intestine (Eggermont et al. 1971). Recently, enter-
opeptidase has been reported to be activated from an
inactive precursor (proenteropeptidase) by duodenase, a
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newly discovered serine protease expressed in the duo-
denum (Zamolodchikova et al. 2000).
Hadorn et al. (1969) first identified a case of con-
genital enteropeptidase deficiency (MIM 226200) in an
infant with failure to thrive, chronic diarrhea, low se-
rum protein, and generalized edema. Trypsin activity in
a duodenal-juice sample was low but was restored to
normal when isolated enteropeptidase was added. Sev-
eral similar cases were described subsequently (Polon-
ovski et al. 1970, Haworth et al. 1971; Pardou et al.
1975; Follett and Macdonald 1976; Lebenthal et al.
1976; Ghishan et al. 1983; Green et al. 1984; Marshall
et al. 1989). These reports consider two families with
affected siblings (Tarlow et al. 1970; Haworth et al.
1975), including one family with affected individuals of
either gender, a finding suggesting autosomal recessive
inheritance (Haworth et al. 1975). On the basis of the
isolation of a partial bovine enteropeptidase cDNA
(LaVallie et al. 1993), Kitamoto et al. (1994, 1995)
cloned the cDNAs containing the complete coding
regions of bovine and human proenteropeptidase and
mapped the human gene to chromosome 21q21, by
FISH. According to the deduced amino acid sequence,
enteropeptidase is a serine protease. The active two-
chain enteropeptidase is derived from a single-chain pre-
cursor (Kitamoto et al. 1994).
The characterization of the genomic organization of
the proenteropeptidase gene has enabled us to perform
mutation analysis of genomic DNA from the original
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Table 1
Sequences of Oligonucleotide Primers Annealing to Exon-Flanking Intronic DNA, Used for
Amplification and Sequencing of Coding Exons of the Proenteropeptidase Gene
Fragment
OLIGONUCLEOTIDE PRIMER
(5′r3′)
Forward Reverse
Exon 1 CAGTTCTTAAATTAGCAAGCC CTGACACTAAAGTGTGTACATTC
Exon 2 CAGAGCTAACACATCAGGC TCACAGTGAGAAAATGGTG
Exon 3 ACTCTAAGCAGAACATAAAGATTG GCCACTTTGCTTAATCCTC
Exon 4 GAATTGAACACAAATCAGTGG GTAAATGTGTCACCTCAGG
Exon 5 AATGACATACTTCTAAATGGACAC TAGCCCTAAATATGTTGTTTACTG
Exon 6 TAAATATTCCTATGGCAGTTGAAG AGTGAGGGAGGATAAAACAGAAG
Exon 7 AATGTTTTGCAGCCAATTTGAATC AAAGCAATAAGACGTTGCATCAG
Exon 8 GATATCATATTATGTGGTGTTCAC AAAATCAAAGGGAAAACATACCAC
Exon 9 ATAGATCAACTGACAAACTGATAG TAAGTTCTAAGAAGAGAAAGATGC
Exon 10 GAAGTATAAGCTGTATAAGGTTAG GACTTTTGCATTTAATGCTGCTC
Exons 11–13 TCTTTCCTGCTTACAAAGTCTAC GTGCCCAGCTAATTTGTGTTTG
Exon 14 AGCATTTACCCTAACATGACTC ATTTATAATCTACTTTGCTGCGTC
Exon 15 TGAAATTCTCAAGAGAGTGAAGC CGTTTACAACCTTTACAATATTCAG
Exon 16 GAGATGTGGGGTACATTTC ATTCTGTACACCTTTGCTG
Exon 17 GTACTCCAGAATCATCCATTTG TCTTTCTTTGACACTGTAGAGTC
Exon 18 TATAGTCACAGTGCTGTGC GTAATAAAAAGGTTTGCAAATCTC
Exon 19 GTCCATAGCATTAAGGAAC CAAATCTGAGTGGGTTCAAC
Exons 20 and 21 CATATATGAGACATTAAGATGTCC AATGTATCTCTATTTTCATACATGAC
Exon 22 TTCTGAAATGTCATGATGAAGATC GCTTTTATGAATTAATGC
Exon 23 CTAAAGGGCCACCAGTGGTAGC CATTCACAGGATATTATGACAG
Exon 24 AGTTCATTCAAGGATGCATGTTG ATGAAATAACTATAACACCAGTGC
Exon 25 TGAGAATATATACAGATGACTTGC CCATGCTTTCTAGAGTAGAATGG
Exon 12 forward CTCTGAAAAGGACTTATTCTAATG
Exon 13 forward CAAGAAGAATCAAGTCAGAG
Exon 21 forward GAGTTTTATGTCACCTGAAG
patients in whom enteropeptidase deficiency was di-
agnosed 125 years ago. Here we provide evidence that
proenteropeptidase-gene mutations are indeed the mo-
lecular cause of congenital enteropeptidase deficiency in
these patients.
Material and Methods
Genomic-Library Screening and Determination of
Gene Structure
A human genomic DNA PAC library (Ioannou et al.
1994) was screened with an a[32P]-dATP–labeled pro-
enteropeptidase cDNA probe (Screening Service of the
Resource Center of the German Human Genome Pro-
ject, Heidelberg/Berlin; see the Resource Center/Pri-
mary Database web site). Two overlapping clones rep-
resenting the entire proenteropeptidase gene (clones
LLNLP704L19841Q3 and LLNLP704L19841Q3) were
identified, and their identity was confirmed by PCR and
FISH analyses (Lichter et al. 1990). Exon-exon PCR
products were generated from PAC DNA templates and
were sequenced from either end by the rhodamine fluo-
rescent dideoxy-dye–terminator method (Perkin-Elmer),
to clarify the gene structure.
Samples from Patients
Blood samples were donated in accordance with con-
sent principles. In family 1 (Haworth et al. 1975), two
affected siblings of either gender had been diagnosed on
the basis of biochemical testing. Both of these patients
and their parents were available for DNA analysis. In
family 2, a single case had been reported (Haworth et
al. 1971). In this man, the coincidence of congenital
enteropeptidase deficiency and celiac disease had been
reported only recently (Moroz et al. 2001). His parents
and two daughters were available for DNA analysis. In
both families, residual enteropeptidase activity in af-
fected individuals was below the limit of detection. All
patients were untreated and free of symptoms in
adulthood.
Mutation Analysis in Patients with Congenital
Enteropeptidase Deficiency
Oligonucleotide primers corresponding to exon-flank-
ing intronic sequences (table 1) were used to amplify and
directly sequence all 25 coding exons from blood genomic
DNA, by an ABI 377 DNA sequencer (Perkin-Elmer).
Polymorphisms were originally detected in patient sam-
ples. Population studies of these polymorphismswere per-
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Figure 1 Mutations in the proenteropeptidase gene. A, Analysis of index patient in family 1. Nonsense mutations were identified in exons
18 and 22. B, Analysis of index patient in family 2, which led to identification of a nonsense mutation in exon 8 and of a frameshift mutation in
exon 23.
formed on genomic DNA from unrelated healthyGerman
blood donors.
Results
Structural Organization of the Proenteropeptidase
Gene
The human proenteropeptidase gene consists of 25 ex-
ons (24 introns) and spans ∼88 kb of genomic DNA se-
quence. Exon-flanking intronic sequence of a length suf-
ficient to allow exon amplification was obtained for all
coding exons. After deposition of our data in the Gen-
Bank database (GenBank accession numbers Y19124–
Y19143), the proenteropeptidase-gene sequence (Gen-
Bank accession number AL078474) was independently
released as part of the chromosome 21 sequencingproject.
This database entry confirmed our findings.
Mutation Analysis in Patients with Congenital
Enteropeptidase Deficiency
In family 1, segregation analysis using a newly iden-
tified polymorphic CA repeat in intron 6 showed that
the two affected siblings had inherited identical alleles.
Sequencing of genomic DNA containing the entire cod-
ing region revealed two heterozygous nonsense muta-
tions (2135CrG [S712X] in exon 18 and 2569CrT
[R857X] in exon 22; fig. 1). Segregation analysis of the
defective alleles (fig. 2) demonstrated that both patients
had, in fact, inherited one defective allele from each par-
ent, thus yielding proof of compound heterozygosity. In
family 2, a heterozygous nonsense mutation was iden-
tified in exon 8 (781CrT [Q261X]; fig. 1). In exon 23,
we found a heterozygous deletion of 2 bp (del 2707–
8GT) leading to a frameshift mutation (FsQ902; fig. 1).
This mutation results in a premature termination of
translation at amino acid 930, following 28 false amino
acid residues at the carboxy terminus. Segregation anal-
ysis including parents and progeny of the index patient
clearly demonstrated compound heterozygosity (fig. 2).
Identification and Characterization of Polymorphisms
Sequencing of exon-intron boundaries led to the iden-
tification of a polymorphic site, a CA repeat at the 5′
end of intron 6, that was characterized further. The anal-
ysis of DNA samples from 81 normal individuals (162
chromosomes) revealed the existence of 10 different al-
leles. The number of CA repeats ranged from 18 to 27.
The observed heterozygosity index was 0.82 (calculated,
0.84), indicating Hardy-Weinberg equilibrium.
A frequent single-nucleotide dimorphism (1473GrA
[A491A]) was detected in exon 13. Allele frequencies
and distributions are given in table 2. Additionally, we
identified a sequence alteration (1472CrT [A491V])
within exon 13 of family 2 but not in any of 96 normal
chromosomes analyzed; it was linked to a nonsense mu-
tation (Q261X; fig. 2), such that it could not be deter-
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Table 2
Distribution of Genotypes of a Frequent
Single-Nucleotide Dimorphism (1473GrA) in
Exon 13 of the Proenteropeptidase Gene in
Healthy Unrelated Individuals from Southern
Germany
GENOTYPE
NO. OF GENOTYPESa
Observed Expected
A/A 4 3.5
G/A 18 18.9b
GG 26 25.6
Total 48 48.0
a Data are based on allele frequencies of 0.73
and 0.27 for the G and A alleles, respectively,
and indicate Hardy-Weinberg equilibrium.
b x2 p 0.05; Pp.73.
Figure 2 Segregation analysis of families with congenital enteropeptidase deficiency. The sequence alterations of the pathogenic mutation are
underlined; the three-digit numerals 241, 237, 231, 229, and 235 denote the fragment lengths of the intron 6 polymorphic CA repeat. In both
families, defective alleles are inherited from heterozygous parents. Note that the 1472CrT (A491V) mutation (or rare polymorphism) in family 2
is part of an allele also affected by a nonsense mutation. Position 1473 is dimorphic (G/A) and informative in family 2 (i.e., the 781CrT mutation
segregates with the T allele) but not in family 1.
mined whether it confers functional compromise. This
finding can be interpreted either as a defective allele hav-
ing acquired another mutation or as a rare polymor-
phism not appearing in 96 normal chromosomes.
Discussion
Congenital enteropeptidase deficiency is characterized by
severe protein malabsorption during early infancy. To
date, the diagnosis has been made solely on the basis of
the inability of a duodenal-juice sample to activate tryp-
sinogen and in vitro restoration by the addition of purified
enteropeptidase (Hadorn et al. 1969). The human proen-
teropeptidase cDNA has been cloned, and the gene has
been mapped (Kitamoto et al. 1995). Mutation analyses
of the proenteropeptidase gene, to trace the biochemical
defect back to a genetic defect, have not previously been
performed. To amplify and sequence genomic DNA from
affected individuals, we clarified the exon-intron structure
of the proenteropeptidase gene. Interestingly, the exon
organization reflects the modular-domain organization of
the proenteropeptidase-gene product as observed by Ki-
tamoto et al. (1994, 1995) (fig. 3). With the exception of
the serine protease domain, functional analyses of enter-
opeptidase domains have not yet been performed. It is
remarkable that primary-structure “modules” other than
the serine protease domain are shared by some serine
proteases, such as C1r (fig. 3).
Sequencing the entire coding region, we identified com-
pound heterozygosity for mutations in the affected in-
dividuals of both families investigated. Newly identified
polymorphisms have been instrumental in segregation
analyses. Since the active serine protease domain is po-
sitioned at the carboxy terminus (Kitamoto et al. 1994),
terminations of translation amino terminally to this do-
main—such as in the cases of Q261X in exon 8 and
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Figure 3 Position of mutations (red arrows), in relation to proenteropeptidase exon organization, domains, and amino acid residues forming
the active site of the serine protease domain (H825, D876, and S971 [blue arrows]). All four mutations identified are null mutations predicting the
absence of a correctly formed active site. The previously described modular structure of proenteropeptidase domains, based on primary-structure
comparison, correlates with exon boundaries. SAp signal/anchor sequence; LDLRp LDL receptor–like domain; Mucp mucin-domain; Meprin
p meprin-like domain; C1r/s p complement component C1r-like domain; MSCR p macrophage scavenger receptor–like domain.
S712X in exon 18—must be predicted to result in abol-
ishment of enzymatic function. The two other mutations
lead to truncationwithin the serine protease domain. The
three-dimensional structure of the serine protease do-
main of enteropeptidase (Protein Data Bank accession
number 1ekb) showing the expected catalytic triad of
serine proteases is conserved (Lu et al. 1999) and consists
of H825, D876, and S971 in human enteropeptidase (Ki-
tamoto et al. 1995). Residue S971 is the active-site nu-
cleophile and is required for substrate cleavage, as de-
picted in figure 2a in the report by Lu et al. (1999). This
active-site residue is predicted to be missing in proteins
encoded by alleles with the mutations R857X (exon 22)
and del2707–2708GT (FsQ902, exon 23). Although not
studied in direct-expression experiments, both the nature
of the mutations found and their location in relation to
the active site of the enzyme allow no prediction other
than that these alleles must be null alleles. This is in
accordance with the biochemical phenotype described
earlier in these patients. Our data lead to the conclusion
that proenteropeptidase-gene defects are the molecular
cause of congenital enteropeptidase deficiency.
In the index patient in family 2, evidence of celiac
disease has been reported only very recently (Moroz et
al. 2001). In light of this, it is important that we have
found disruptive mutations in the proenteropeptidase
gene. We thereby have confirmed that enteropeptidase
deficiency is not secondary to morphological changes
observed in celiac disease.
All patients investigated had been diagnosed as in-
fants, 125 years ago. In adulthood, they have had ap-
parently normal lives, with absence of gastrointestinal
symptoms and with normal body weight, even when
pancreatic-enzyme substitution has been discontinued.
With this knowledge, we had expected to identify mis-
sense mutations that might allow for the possibility that
some residual enteropeptidase activity had not been de-
tected in the original investigations; however, since all
mutations found predict abolishment of enzymatic func-
tion, we conclude that protein digestion depends on the
action of enteropeptidase during infancy only. Activa-
tion of trypsinogen by enteropeptidase-independent
mechanisms must be predicted to occur. In fact, it has
previously been shown that trypsinogen does have an
inherent activity by which it can self-activate, albeit at
a very slow rate (Kay and Kassell 1971). Furthermore,
it is known, from earlier studies, that trypsin, once re-
leased from its precursor, promotes further activation
of trypsinogen, in a positive-feedback fashion (Davie
and Neurath 1955). This explains the observation that
active trypsin, chymotrypsin, and carboxypeptidase A
are detected in the feces of patients with enteropeptidase
deficiency (Hadorn et al. 1969). We speculate that the
self-activation of trypsinogen and the activation by tryp-
sin independently of enteropeptidase activity may suf-
fice for protein digestion in the human adult but not in
the human infant, given that the infant’s relative de-
mand for protein digestion is much higher. Alternative,
unknown mechanisms of enteropeptidase-independent
trypsinogen activation may also exist.
Congenital enteropeptidase deficiency is most likely
underdiagnosed. In cases of failure to thrive during early
infancy, accurate therapy, either by the use of hydro-
lyzed infant formula or by the substitution of pancreatic
enzymes, is often initiated prior to a precise diagnosis,
because of the lack of a convenient test. DNA analysis
may improve this situation.
Congenital enteropeptidase deficiency may be genet-
ically heterogeneous. It is conceivable that duodenase
mutations resulting in defective activation of proenter-
opeptidase may lead to disease similar to enteropepti-
dase deficiency. As more patients are genetically ana-
lyzed in the future, it will be interesting to see whether
genetic defects in the proenteropeptidase gene can be
identified in every case; if not, such patients would be
candidates for duodenase-gene mutations.
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